Data from Medivir’s MIV-818 phase 1b study to be presented at the ESMO Congress
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)” will be presented by Dr Debashis Sarker, King´s College London, at the European Society for Medical Oncology (ESMO) congress. The Abstract will be released on the ESMO website 13 September 00.05 CEST . The results from the completed phase 1b monotherapy dose escalation part of the study (